Hepatocyte lineage cells

• US 8,574,905 B2
• Filed: 08/02/2011
• Issued: 11/05/2013
• Est. Priority Date: 04/28/2006
• Status: Active Grant

• Current Assignee: Viacyte Incorporated (Vertex Pharmaceuticals Incorporated)
• Original Assignee: Viacyte Incorporated (Vertex Pharmaceuticals Incorporated)
• Inventors: D'Amour, Kevin, Baetge, Emmanuel E.
• Primary Examiner(s): Paras, Jr., Peter
• Assistant Examiner(s): Montanari, David A
• Application Number:
  US13/196,381
• Publication Number:
  US 20110294211A1
• Time in Patent Office: 826 Days
• Field of Search: 435/325, 435/377
• US Class Current: 435/377
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/119 Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
• CPC Class Codes: C12N 2501/155 Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/067 Hepatocytes
• CPC Class Codes: C12N 5/0672 Stem cells; Progenitor cells; Precursor cells; Oval cells

Abstract

Disclosed herein are methods for producing liver precursor cells as well as hepatocyte cells form pluripotent and/or multipotent cells. Also disclosed herein are methods of enriching isolating and/or purifying liver precursor cells and/or hepatocyte cells. Further disclosed are compositions comprising cell cultures and cell populations that are enriched for liver precursor cells or hepatocyte cells.

Claims

1. A method of enriching a population of liver precursor cells, said method comprising:

providing a cell population comprising human pluripotent cells with a growth factor of the TGFβ

superfamily;

allowing sufficient time for at least a portion of said human pluripotent cell population to differentiate into definitive endoderm cells;

providing said cell population comprising definitive endoderm cells with BMP4 and FGF10;

allowing sufficient time for at least a portion of said definitive endoderm cells to differentiate into liver precursor cells;

contacting said cell population comprising liver precursor cells with a reagent that binds to a marker selected from the group consisting of DPP4, NOSTRIN, DOK4, SLC35D1, OCDH17, FN1, HLA-C, HLA-B, CYP4X1, CPHA6, PP1057 HPX and DGKB; and

separating cells bound to said reagent from cells that are not bound to said reagent, thereby producing an enriched population of liver precursor cells.